Introduction
Pax3 transcriptional activity is required for normal embryonic development of both humans and mice. Mutations in PAX3 in humans gives rise to Waardenburg syndrome (Hoth et al., 1993; Baldwin et al., 1994) , which is characterized by pigmentation, craniofacial, limb and hearing defects. Genetic analysis of splotch (sp) mice (Tassabehji et al., 1994) , which harbour a null mutation in Pax3, further revealed a role for this transcription factor in the development of the neural tube, peripheral nervous system (Tremblay et al., 1995) and limb musculature (Bober et al., 1994; Epstein et al., 1996; Conway et al., 1997b) , as well as in a number of tissues, which require specific migrating neural crest cell populations including the heart and the dermis (Conway et al., 1997a) .
Pax3 encodes an N-terminal paired domain (PD) DNA-binding motif as well as a C-terminal homeodomain (HD; Chalepakis et al., 1994a) . Detailed mutational analysis of murine Pax3 and Pax3 mutants from Waardenburg patients revealed the reciprocal influence of these two domains on their respective DNA-binding activities (Fortin et al., 1997) . For example, specific point mutations in the PD which abrogated DNA-binding activity of this motif also altered binding to DNA of the adjacent HD, in some cases abrogating binding completely. Likewise, the R53G mutation in the HD prevents DNA binding by both the HD and the adjacent PD. Transcriptional activity of Pax3 is also modulated by other motifs, including the region between the two DNA-binding domains, the octapeptide domain (Chalepakis et al., 1994a) , which modulates homodimerization, and the Cterminal transactivation domain (Cao and Wang, 2000) . Pax3 activity is further regulated through binding of other nuclear factors. For example, both Daxx and pRB (Wiggan et al., 1998) associate with Pax3, repressing Pax3-dependent transcription in a dose-dependent manner.
Altered Pax3 activity is associated with malignant transformation in muscle (Anderson et al., 1999; Xia et al., 2002) and in skin (Vachtenheim and Novotna, 1999; Blake and Ziman, 2003; Poser and Bosserhoff, 2004) . For example, one reciprocal translocation (t(2;13)(q35;q14)) characteristic of human alveolar rhabdomyosarcomas (ARMS) results in fusion of the transactivation domain of the Forkhead-family protein, Forkhead-Box O1a (FOXO1a; formerly known as ForkHead (FKHR); Kaestner et al., 2000) , to the Nterminus of Pax3 (Shapiro et al., 1993) . The resultant fusion protein, Pax3/FKHR, exhibits greater transcriptional activity than Pax3 (Fredericks et al., 1995) and is refractory to repression of its activity by Daxx . Pax3/FKHR induces cellular transformation, demonstrated following its expression in chick embryo fibroblasts (Scheidler et al., 1996) , NIH3T3 cells (Lam et al., 1999) or the human rhabdomyosarcoma cell line, RD (Anderson et al., 2001) . Using a reciprocal approach, expression of Pax3 fused to the repression domain of KRAB suppressed the transformed phenotype in rhabdomyosarcomas expressing Pax3/FKHR (Fredericks et al., 2001) . That the transformed phenotype in rhabdomyosarcomas requires Pax3 or Pax3/FKHR expression was demonstrated using siRNA (Elbashir et al., 2001 ), repression of Pax3 or Pax3/FKHR expression, resulting in programmed cell death (Bernasconi et al., 1996) . However, confounding the notion that Pax3/FKHR is a potent oncogene are sp mice with a 'knocked-in' allele of Pax3/FKHR (Lagutina et al., 2002; Relaix et al., 2003) . These animals exhibit a partial rescue of the sp phenotype but do not develop tumours, potentially due to the low levels of expression of Pax3/FKHR.
The structural basis for the oncogenic potential of Pax3/FKHR relative to Pax3 is not well defined. Unlike the important interactions between the PD and HD of Pax3 required for normal activity, transformation of cells in culture requires only the HD, an intact PD apparently dispensable in this assay (Lam et al., 1999) . Pax3/FKHR is also refractory to the inhibitory effects of repressors such as Daxx and exhibits greater transcriptional activation activity than wild-type Pax3 (Fredericks et al., 1995) . The oncogenic potential of Pax3/FKHR may also stem from its ability to regulate the expression of factors unaffected by Pax3. For example, Pax3/FKHR, but not Pax3, specifically induces PDGFaR promoter activity and expression (Epstein et al., 1998) . Consistent with the transforming activity of Pax3/FKHR requiring only the HD, activation of the PDGFaR promoter required a DNA sequence identical to that recognized by paired-like HDs. Thus, while Pax3/FKHR can bind to and induce promoter activity through PD consensus sequences, the HD appears to be utilized in some contexts to drive gene expression. These data suggest that transformation by Pax3/FKHR may occur through altered potency of its transcriptional activity and through the regulation of unique gene targets not recognized by Pax3.
We determined previously that Pax3 induces a mesenchymal to epithelial transition (MET) in number of cell lines, including the human osteosarcoma, SaOS-2 . This transition is accompanied by significant alterations in cytoskeletal structure. Specifically, dense peripheral bands of actin replace stress fibres, while microtubules become oriented in the z-plane as these cells form polarized cell-cell contacts. We have now compared potential gene targets of Pax3 with those of its oncogenic counterpart, Pax3/FKHR, as well as determined the effect of Pax3/FKHR on SaOS-2 cell morphology. These data reveal that Pax3/FKHR induced a morphological transition in these cells with significantly increased kinetics relative to Pax3-expressing cells. We showed further that Pax3/FKHR alters the expression of a distinct but overlapping set of factors relative to those regulated by Pax3, and that for some of these factors, their regulation is cell-type specific.
Results

Pax3/FKHR is a more potent activator of MET than Pax3
Expression of Pax3 in the human osteosarcoma cell line, SaOS-2, causes a MET . During this transition, cells condense, formed compact aggregates and become polarized. We predicted that the oncogenic variant of Pax3, Pax3/FKHR, would also induce this transition. SaOS-2 cells, which do not express endogenous Pax3, were infected with adenovirus expressing green fluorescent protein (GFP) and either bgalactosidase (bgal), flag-tagged Pax3 (Pax3 We determined next that Pax3/FKHR induced a MET in cells resistant to a Pax3-induced MET. For example, since pRB represses the activity of Pax3 (Wiggan et al., 1998) , we predicted that Pax3-dependent induction of a MET in the pRB-positive human osteosarcoma, U2-OS, would be retarded. As Figure  4a and b illustrates, a small but significant reduction in the size of U2-OS cells occurs following expression of Pax3. However, the cells fail to develop the characteristics of Pax3-induced SaOS-2 cells. In contrast, expression of Pax3/FKHR induced U2-OS to form tight aggregates of highly compact cells resembling Pax3-expressing SaOS-2 cells.
Thus, Pax3/FKHR induces a morphological change in SaOS-2 cells with accelerated kinetics relative to Pax3 and induces a morphological transition in a pRBexpressing cell line that is resistant to the effects of Pax3 activity. Pax3/FKHR is a more potent transcriptional activator than Pax3 (Fredericks et al., 1995; Bennicelli et al., 1996) . The presence of the FKHR domain also alters the specificity of DNA sequence recognition, consistent with its ability to differentially regulate at least one gene (PDGFaR; Epstein et al., 1998) . Thus, we determined whether Pax3/FKHR regulated a distinct set of factors relative to Pax3 during the induced MET in SaOS-2 cells. RNA isolated from control SaOS-2 cells or cells expressing bgal or Pax3/FKHR 48 h postinfection was subjected to microarray analysis using the Affymetrix U133A Human Genome Microarray ( Figure 5 , Transition 1). Repetition of this analysis was performed using RNA isolated in an independent transition 12 months later ( Figure Tables 1 and 2 ). For example, the cardiac calcium flux regulator, phospholamban (PLN), was strongly induced (6.2-fold induction) by Pax3/FKHR but was unaffected by Pax3 (Figure 6b ). Figure 6b also illustrates an example of factors, which were induced following expression of Pax3/FKHR but were repressed in the Table 3 ). Parathyroid hormone-like hormone (PTHLH) participates in the development of a number of tissues. Importantly, PTHLH expression in breast tumours (Bouizar et al., 1993) and rhabdomyosarcomas (Blake and Ziman, 2003) is responsible for metastases of these tumours to bone. While the microarray analysis detected only a modest induction by Pax3/FKHR or repression by Pax3, the densitometry of the RT-PCR reactions consistently produced greater than twofold induction by Pax3/FKHR or repression by Pax3, respectively, of PTHLH message. Together, these data reveal a global alteration in gene expression during the morphological transition induced Based on the global changes in gene expression observed, we hypothesized that coordinated changes in the expression of factors within defined genetic pathways would occur. As Figure 7 illustrates, coordinated alteration in the expression of factors involved in BMP4 signalling occurred. Specifically, BMP4 levels were repressed by both Pax3 and Pax3/FKHR. Further, the BMP4 agonist, BMP1 (Wardle et al., 1999a, b) , was also repressed, while an antagonist of BMP4, twisted gastrulation (TWGS; Yu et al., 2000; Chang et al., 2001; Ross et al., 2001; Scott et al., 2001) , was induced in these cells. Since BMP4 signalling was repressed, we predicted and determined that one potential target of BMP4 signalling, Dlx3 (Luo et al., 2001; Park and Morasso, 2002) , was also repressed following Pax3 and Pax3/ FKHR expression.
Direct transcriptional targets of Pax3 and Pax3/FKHR
Altered gene expression profiles in SaOS-2 cells following expression of Pax3 or Pax3/FKHR may arise due to indirect regulation of promoter activity. We began to define direct targets of Pax3 and Pax3/FKHR by blocking protein synthesis using cycloheximide (Figure 8 ). Cells were infected with virus expressing bgal, Pax3 or Pax3/FKHR, and cycloheximide was added 1, 2 or 3 h postinfection to prevent further protein synthesis. Cell harvested after 24 h of cycloheximide treatment maintained low levels of Pax3 or Pax3/FKHR protein relative to untreated cells (Figure 8a) . Changes in the levels of expression of factors induced by Pax3 or Pax3/FKHR were determined using RNA isolated after (Figure 8b-c) . EPHA4 was induced by both Pax3 and Pax3/FKHR, while SLIT2 and CNR1 appeared to be induced only by Pax3/FKHR under these conditions. PTHLH was induced by Pax3/FKHR, while a small, reproducible decrease of PTHLH levels in Pax3-expressing cells was also observed. These data suggest, therefore, that these factors may be direct targets of Pax3/FKHR and, for some, Pax3.
Confirmation of direct regulation by Pax3 or Pax3/ FKHR was obtained by performing chromatin immunoprecipitations ( Figure 9 ). CNR1 was chosen initially since inspection of the 5 0 region flanking the transcriptional start site of its annotated sequence from the human genome revealed a Pax3 consensus site (reverse orientation) at -357. As Figure 9a illustrates, both Pax3 and Pax3/FKHR co-immunoprecipitated a crosslinked genomic DNA fragment adjacent to this Pax3 DNAbinding consensus sequence in the putative CNR1 promoter region. Similarly, EPHA4, which is strongly induced by Pax3/FKHR, and EPHA2, which is suppressed, encodes Pax3 DNA-binding consensus sequences at À83 and À76, respectively. For EPHA4, this site is identical in sequence and position to the murine EphA4 promoter, while the PD site for the murine EphA2 promoter is positionally identical and differs by a single nucleotide. Using the a-Pax3 antibody for a ChIP on Pax3/FKHR-expressing cells, EPHA4-and EPHA2-specific fragments were isolated from both Cell-specific gene regulation by Pax3 and Pax3/FKHR S Begum et al putative promoters. Repression of transcription from the EPHA2 promoter but not the EPHA4 promoter was also evident since amplification of a band for EPHA4 but not EPHA2 band was observed for the a-polymerase II (a-pol II) antibody.
Cell-type-specific gene regulation by Pax3 and Pax3/ FKHR
The spectrum of genes we identified by microarray analysis did not overlap significantly with the results from previous studies attempting to identify Pax3 or Pax3/FKHR target genes (Khan et al., 1998 (Khan et al., , 1999 Mayanil et al., 2001 ). Thus, we tested the hypothesis that altered expression of some gene targets would be cell-type specific. Pax3 and Pax3/FKHR were ectopically expressed in the human rhabdomyosarcoma, RD, which expresses low levels of endogenous Pax3 and Pax7. Changes in the expression of specific factors were compared to endogenous levels of expression in the rhabdomyosarcoma, RH30, which expresses low levels of endogenous Pax3/FKHR ( Figure 10 ). As expected, CNR1 was induced by both Pax3 and Pax3/FKHR in RD cells, similar to its induction in SaOS-2 cells. CNR1 was also constitutively expressed in RH30 cells. Likewise, induction of ephrin B2 (EFNB2) by Pax3/FKHR, but not Pax3, as well as expression in RH30 cells was observed, similar to EFNB2 expression in SaOS-2 cells. However, a number of gene targets were distinctly regulated in RD cells relative to SaOS-2 and RH30. For example, in contrast to SaOS-2 cells where both Pax3 and Pax3/FKHR repressed BMP4 expression, it was strongly induced by Pax3/FKHR, but not Pax3, in RD cells. In the case of SLIT2, while strong induction by Pax3/FKHR occurred in SaOS-2 cells, neither Pax3 nor Pax3/FKHR affected Slit2 levels in RD cells, although expression was observed in RH30. For EPHA4, Pax3/ FKHR, but not Pax3, induced expression unlike in SaOS-2 cells where EPHA4 was induced by both factors. These data reveal, therefore, that regulation of at least some Pax3 and Pax3/FKHR gene targets is dependent on the specific cell type in which these transcription factors are expressed.
Discussion
We demonstrated previously that Pax3 induces a MET in SaOS-2 cells . As illustrated here, expression of the oncogenic variant of Pax3, Pax3/FKHR, was a considerably more potent driver of this transition than Pax3. This increased activity was reflected by the observation that, while U2-OS cells showed only a limited response to the expression of Pax3, Pax3/FKHR induced morphological changes and aggregation similar to SaOS-2 cells.
The stronger activity of Pax3/FKHR was consistent with previous data demonstrating the increased transcriptional activity of the oncogenic (Scheidler et al., 1996) fusion protein (Fredericks et al., 1995) . The microarray analysis presented here revealed that a large number of factors were either induced or repressed by Pax3/FKHR and Pax3. In all cases, where both Pax3/ FKHR and Pax3 induced expression, stronger induction occurred with Pax3/FKHR. Consistent with the accelerated kinetics of the morphological transition induced by Pax3/FKHR relative to Pax3, induction or repression of target genes by Pax3/FKHR was also accelerated.
We identified a small number of factors induced by Pax3/FKHR but repressed by Pax3. Significantly, PTHLH (also known as parathyroid-related peptide (PTHrP)) behaved in this manner. While important in the embryonic development of a number of tissues, including bone (Vortkamp et al., 1996; Farquharson et al., 2001 ) and the mammary gland (Dunbar and Wysolmerski, 1999; Foley et al., 2001) , PTHLH expression can also result in metastasis to bone in some breast carcinomas (Kissin et al., 1993; Sebag et al., 1994; Bundred et al., 1996) and rhabdomyosarcomas (Kawasaki et al., 1998) . PTHLH expression further gives rise to humoral hypercalcaemia (Bundred et al., 1996; Guise et al., 1996; Kawasaki et al., 1998) , a result of increased bone resorption due to PTHLH-dependent induction of osteoclast activity (Chirgwin and Guise, 2000) . We also identified four potential PD binding sites within the first 550 bp upstream of the PTHLH gene annotated in the human genome sequence (unpublished observation). Thus, the Pax3/FKHR-specific induction of PTHLH may account, in part, for the some of the specific properties of ARMS. Likewise, we identified Pax3/ FKHR-specific targets known to be involved in For example, SLIT2, identified originally as a factor involved in axonal guidance (Hu, 1999; Nguyen Ba-Charvet et al., 1999) , is expressed by a number of transformed cells. In this context, Slit2 recruits vascular endothelial cells, thus promoting angiogenesis as well as establishing a blood supply at distant metastatic tumour sites (Wang et al., 2003) . We also focused on Pax3 or Pax3/FKHR target genes known or likely to be genetically downstream of Pax3. For example, Pax3 is required for proper epithelialization of the developing somite (Schubert et al., 2001) . EPHA4, which is normally expressed in the anterior portion of newly formed somites, is misexpressed in Pax3-deficient embryos (Schubert et al., 2001) . EPHA4 is induced by both Pax3 and Pax3/FKHR in SaOS-2 cells. Inspection of the region 5 0 of the EphA4 gene reveals at least one potential Pax3 PD binding site (Chalepakis et al., 1994b; Chalepakis and Gruss, 1995; Underhill et al., 1995; Underhill and Gros, 1997) at À83 (5 0 CACGTCACCGGC). Likewise, EFNB2, another factor involved in somite development (Durbin et al., 1998; Johnson et al., 2001; Barrios et al., 2003) and polarized trafficking of axons and neural crest cells through the somite (Wang and Anderson, 1997; Koblar et al., 2000; De Bellard et al., 2002) , was induced by Pax3 and Pax3/FKHR in SaOS-2 cells. EFNB2 harbours two Pax3 DNA-binding consensus sequences upstream of the transcript start (À3 and À355). Furthermore, we observed further that MSX2, a known target for repression by Pax3 (Kwang et al., 2002) , was repressed by Pax3/FKHR in SaOS-2 cells (data not shown). More direct evidence of transcriptional regulation of factors by Pax3 and Pax3/FKHR was determined through chromatin immunoprecipitation. Pax3 and Pax3/FKHR coimmunoprecipitated with a segment of CNR1 promoter region 25 bp upstream of a Pax3 PD consensus sequence (À357) and 900 bp downstream of three additional Pax3 DNA-binding consensus sequences. PD sites are also found in the analogous region of the putative murine Cnr1 gene, although not strictly conserved positionally. Expression of CNR1 during embryogenesis in the developing brain and neural tube (Buckley et al., 1998) in a pattern overlapping that of Pax3 (Goulding et al., 1991; Dietrich et al., 1993; Gerard et al., 1995; Terzic and SaragaBabic, 1999) as well as the role of CNR1 (Song and Zhong, 2000) and Pax3 (Epstein et al., 1996; Conway et al., 1997a; Tremblay et al., 1998) in cell migration are consistent with Pax3 potentially regulating CNR1 expression directly.
Other studies have attempted to identify transcriptional targets of Pax3 or Pax3/FKHR through microarray analysis (Khan et al., 1999) or using the 'CASTing' method (Khan et al., 1998) . Comparison between our data with those from these other studies shows a striking lack of overlap in the potential targets. Notably, the gene expression profiles obtained in these studies were determined following expression of Pax3 or Pax3/FKHR in distinct cell lines. However, as we illustrated in Figure 10 , Pax3-or Pax3/FKHR-regulated transcription of at least some factors was cell-type specific. CNR1 was induced, for example, by Pax3/ FKHR in both SaOS-2 and RD cells and is expressed in the Pax3/FKHR-expressing RH30 cells. In the case of BMP4, however, we observed repression of expression in SaOS-2 cells but Pax3/FKHR-dependent induction in RD cells. Additionally, SLIT2 appears to be a target of Pax3/FKHR in SaOS-2 cells and is expressed in RH30 rhabdomyosarcomas, but is refractory to Pax3/FKHR activity in RD cells. We also determined that while CXCR4 is strongly induced by Pax3/FKHR in RD cells (data not shown), as was demonstrated previously (Libura et al., 2002) , no change in expression was seen in Pax3/FKHR-expressing SaOS-2 cells. Thus, comparisons between NIH3T3 cells (Khan et al., 1999) or medulloblastomas (Mayanil et al., 2000 (Mayanil et al., , 2001 with SaOS-2, RD or RH30 cells is likely to reveal divergent sets of gene targets. These data further imply significant limitations in extrapolating microarray data derived from individual cell lines to other rhabdomyosarcomas or to identification of target genes during, for example, Pax3-dependent neural crest cell migration, somite development or in rhabdomyosarcomas.
The data presented in this study, therefore, demonstrated both quantitative and qualitative differences in target gene regulation between Pax3 and its oncogenic variant, Pax3/FKHR. Our genome-wide survey of genes regulated by Pax3/FKHR revealed a number of important potential targets, which are expected to significantly influence the phenotype of rhabdomyosarcomas. Large-scale comparison between Pax3 (RD cells) and Pax3/FKHR-expressing cells (RH30 cells) as well as identification of direct transcriptional targets of these factors in primary cells using large-scale chromatin immunoprecipitations (Weinmann et al., 2001; Wells et al., 2003) is currently in progress.
Materials and methods
Cell culture
The human osteosarcoma, SaOS-2, and human rhabdomyosarcoma, RD, were maintained in Dulbecco's minimal essential medium supplemented with 10% foetal bovine serum (FBS; Sigma, Oakville, Canada). Human RH30 rhabdomyosarcoma and human U2-OS osteosarcoma cell lines were grown in a-MEM supplemented with 15% FBS and Lglutamine.
Antibodies
Rabbit polyclonal a-Pax-3 was obtained from Geneka Biotechnology (Montreal, Canada), a-pol II monoclonal antibody (clone 8WG16) from Covance (New Jersey, USA), goat polyclonal a-b-catenin from Santa Cruz Biotechnology (Santa Cruz, USA), mouse monoclonal a-b-tubulin and TRITC-labelled phalloidin from Sigma chemicals (Oakville, Canada) and a-acetylated histone H4 from Upstate Biotechnology (New York, USA).
Adenoviruses and infection
Adenoviruses expressing GFP and bgal or flagged-tagged Pax3 have been described previously . Pax3/FKHR HA -expressing adenovirus was produced by ligating and HA-tagged Pax3/FKHR (gift from J Epstein; Sublett et al., 1995) into pAd-Track-CMV. Bacterialmediated recombination and adenovirus amplification in 293 cells were performed as described previously (He et al., 1998) . Infection of cell lines were performed as we described previously .
Microscopy and immunofluorescence staining
Morphology of living cells was documented using a Nikon Eclipse TE200 microscope equipped with a Nikon DMX1200 digital camera. Immunofluorescent detection of actin, tubulin and b-catenin in paraformaldehyde-fixed SaOS-2 cells was performed as described previously .
RNA isolation, microarray analysis and RT-PCR
Total RNA was isolated from SaOS-2, RD and RH30 cells using Tri-reagent (Sigma) and the RNeasy Mini Kit. Microarray analysis was performed using the Affymetrix Human U133A microarray according to the protocol of the manufacturer. For verification of expression, RT-PCR was performed using Superscript One step RT-PCR system with Platinum Taq (Invitrogen). PCR products were analysed on 2% agarose gels and quantified using NIH Image software. Primers pairs for specific human factors are as follows:
CNR1
ATC GTG TAT GCG TAC ATG TAT AT ACA GAG CCT CGG CAG ACG T BMP4 TGG ACT TGG CCG ACT ACA CC CCA GTG AAG TTT CCC CCA ATG BMP ATG ATT CCT GGT AAC CGA ATG GCT CAG GAT ACT CAA GAC CA CITED1
ACT TCT GCC AAG GCT CTG AAA GCA GCT AGA TGG AAA GTC CG DLX3 ATG AGT GGC TCC TTC GAT CG GTA CAC AGC CCC AGG GTT G SLIT2
GGT TCC CTC GGA GCA GCA A CCA CGG AAA GCT TTC CTT GC TWSG  GCT GTA AGG AGT GCA TGC TG  CCA GAT TCT CAT GAT GTG AA  PLN  CAG ACT TCC TGT CCT GCT GGT ATC  AGA TCT AGA GGT TGT AGC AGA ACT  PTHLH  ATG CAG CGG AGA CTG GTT CA  GTC TTG AGC GGC TGC TCT TT  EPHB2  AAA ATT GAG CAG GTG ATG GG  TCA CAG GTG TGC TCT TGG TC  EFNB2  GCA AGT TCT GCT GGA TCA AC  AGG ATG TGT TTG TTC CCC GAA TG  EPHA4 AGT TCC AGA CCG AAC ACA GCC TTG GCC ATG CAT CTG CTG CAT CTG GAPDH GTC AGT GGT GGA CCT GAC CT AGG GGT CTA CAT GGC AAC TG
Chromatin immunoprecipitation
At 48 h postinfection, cells were crosslinked for 10 min in 1% formaldehyde. A total of 3 Â 10 6 cells were washed in ice-cold PBS. Chromatin immunoprecipitations were then performed as described previously (Popkin et al., 2003) . The predicted promoter regions of the human CNR1, EPHA2 and EPHA4 genes were obtained from Genbank. Primers were as follows: CNR1 À357 to À457 upstream of the annotated geneforward primer: GCACACTTGTGTCACCAACCTGCTCAT, reverse primer: CCTCAGGTGATCCACCTGCCTCGGCCT; EPHA2 þ 102 to -104 upstream of the annotated geneforward primer: AGACATTCCTGAGGGCGGGC, reverse primer: TCTCGCTCTCGGTCCGATCC; and EPHA4 À25 to À126 upstream of the annotated gene -forward primer: TGTCTGCGCCGCCATTGGCC, reverse primer: AGTTAG GAGAGCAGCGGGCTG.
